Merck touts 20 new ‘blockbuster’ drugs in development with $50 billion potential
Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.
Merck Is Suffering From a Classic Pharma Problem
Blockbuster Keytruda makes up nearly half of Merck’s sales. That’s becoming an issue.
STAT17h
Merck’s earnings miss focused attention on Gardasil. The real issue is Keytruda
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
Merck price target lowered to $112 from $118 at BofA
BofA lowered the firm’s price target on Merck (MRK) to $112 from $118 and keeps a Buy rating on the shares. Q4 results were “decent,” but 2025 ...
Big Pharma, Bigger Bargain: Why Merck Stock Is Too Cheap To Ignore (Upgrade)
Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...
FiercePharma1d
Merck halts Gardasil shipments to China, withdraws $11B sales target as demand nosedives
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...
These Stocks Are Moving the Most Today: Palantir, Alphabet, Tesla, Merck, PayPal, Super Micro, Spotify, Estée Lauder, and More
Palantir stock surges as artificial-intelligence gains drive an earnings and revenue beat, China begins an antitrust probe ...
StockStory.org on MSN1d
Merck’s (NYSE:MRK) Q4 Sales Top Estimates But Stock Drops
Global pharmaceutical company Merck (NYSE:MRK) reported Q4 CY2024 results , with sales up 6.8% year on year to $15.62 billion ...